Skip to main content

Published locations for Tivozanib has PFS benefit over sorafenib in hard-to-treat RCC

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Tivozanib has PFS benefit over sorafenib in hard-to-treat RCC

User login

  • Reset your password
  • /content/tivozanib-has-pfs-benefit-over-sorafenib-hard-treat-rcc
  • /oncologypractice/article/195024/renal-cell-carcinoma/tivozanib-has-pfs-benefit-over-sorafenib-hard
  • /hematology-oncology/article/195024/renal-cell-carcinoma/tivozanib-has-pfs-benefit-over-sorafenib